 |
 Video: What is a Stock Split?
|
|
|
| Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. Co. in-licenses from Pfizer, Inc., the global development and commercialization rights to PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Co. is primarily focused on the development and commercialization of the oral version of neratinib, and its drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. According to our Puma Biotechnology stock split history records, Puma Biotechnology has had 0 splits. | |
|
Puma Biotechnology (PBYI) has 0 splits in our Puma Biotechnology stock split history database.
Looking at the Puma Biotechnology stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Puma Biotechnology shares, starting with a $10,000 purchase of PBYI, presented on a split-history-adjusted basis factoring in the complete Puma Biotechnology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$83.78 |
|
| End price/share: |
$5.01 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-94.02% |
|
| Average Annual Total Return: |
-24.55% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$597.85 |
|
| Years: |
10.00 |
|
|
|
|
|
